Levodopa/Carbidopa Fairmed Healthcare (Carbidopa, Levodopa)

Levodopa serves as a dopamine precursor that crosses the blood‑brain barrier and is converted to dopamine within the central nervous system. Carbidopa blocks peripheral conversion of levodopa, allowing more of the drug to reach the brain and reducing peripheral side effects such as nausea.

The dose of Levodopa/Carbidopa is individualized by the prescribing clinician based on the severity of symptoms, patient age, response to therapy, and any co‑existing medical conditions. No fixed regimen is provided here; the prescriber sets the appropriate dosage and titration schedule.

Safety data for Levodopa/Carbidopa in pregnancy and lactation are limited. It is generally classified as a drug with unknown risk, and use is only considered when the potential benefits to the mother outweigh possible risks to the fetus or infant. Consultation with a specialist is advised.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Levodopa/Carbidopa is a dopamine precursor, whereas dopamine agonists directly stimulate dopamine receptors. Levodopa/Carbidopa typically offers stronger symptomatic relief but may be associated with motor complications over time. Choice of therapy depends on disease stage, patient age, and tolerance of side effects.

The product should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the tablets in a dry place and avoid exposure to excessive heat or humidity to maintain potency.

Levodopa/Carbidopa is taken orally, usually as a tablet, with a full glass of water. It is often recommended to take the medication on an empty stomach or with a low‑protein snack to enhance absorption, unless the prescriber advises otherwise.

Serious risks include the development of dyskinesias (involuntary movements), psychosis or hallucinations, severe orthostatic hypotension that can lead to fainting, and rare cardiac arrhythmias. Patients should be monitored regularly for these events, and any sudden changes should be reported to a healthcare professional.

Individuals with known hypersensitivity to levodopa, carbidopa, or any excipients should avoid the medication. It is also contraindicated in patients with narrow‑angle glaucoma, severe cardiovascular disease, or those taking non‑selective MAO inhibitors. A thorough medical review is essential before initiating therapy.